Gonorrhea Therapeutics Market Report 2026

The gonorrhea therapeutics market size has grown strongly in recent years. It will grow from $1.97 billion in 2025 to $2.08 billion in 2026 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to global STI prevalence, antibiotic availability, public health interventions, hospital infection treatment protocols, diagnostic laboratory expansion.

The gonorrhea therapeutics market size is expected to see steady growth in the next few years. It will grow to $2.52 billion in 2030 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to resistance-driven drug innovation, increased sexual health screening, public health funding, novel antibiotic development, telehealth STI management. Major trends in the forecast period include rising antibiotic resistance monitoring, increased use of combination antibiotic therapy, expansion of STI screening programs, growth of public health awareness campaigns, improved diagnostic testing adoption.

The rising incidence of sexually transmitted infections (STIs) is expected to drive the growth of the gonorrhea therapeutics market in the coming years. STIs are infections transmitted through sexual contact and caused by bacteria, viruses, or parasites. The increase in STIs is influenced by factors such as unprotected sex, lack of awareness or education, multiple sexual partners, reduced condom use, and delayed or insufficient testing and treatment. Gonorrhea therapeutics target Neisseria gonorrhoeae bacteria to treat infections, prevent complications, and reduce transmission. For example, in June 2024, a report by the National Institute for Public Health and the Environment, a Netherlands-based government agency, showed that gonorrhea cases diagnosed at sexual health clinics rose from 10,600 in 2022 to 13,853 in 2023, reflecting a 31% increase. Therefore, the rising prevalence of sexually transmitted infections is driving the growth of the gonorrhea therapeutics market.

Major companies in the gonorrhea therapeutics market are developing innovative solutions such as rapid polymerase chain reaction (PCR) tests to provide fast and accurate detection of pathogens and their characteristics, including antibiotic resistance, at the point of care. A rapid PCR test quickly amplifies and identifies specific DNA or RNA sequences, enabling timely pathogen detection. For instance, in February 2024, Visby Medical, Inc., a US-based medical technology company, launched a gonorrhea test that includes an antimicrobial resistance assessment. This rapid diagnostic test detects Neisseria gonorrhoeae and evaluates its susceptibility to ciprofloxacin, an antibiotic to which some strains have developed resistance. The test operates on a portable, instrument-free PCR platform for immediate point-of-care testing. Developed with funding from the US non-profit CARB-X, the company plans to expand the test to detect other STIs such as Chlamydia trachomatis and Trichomonas vaginalis in men.

In November 2024, the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a US-based biopharmaceutical organization, partnered with the Clinton Health Access Initiative (CHAI) to enhance antimicrobial resistance (AMR) response and address gonorrhea. Through this collaboration, CARB-X and CHAI aim to evaluate clinical needs and overcome market barriers for gonorrhea diagnostics, prevention, and treatment in low- and middle-income countries, with a focus on drug-resistant Neisseria gonorrhoeae. The partnership seeks to improve patient management and expand access to effective AMR solutions. CHAI is a US-based health organization dedicated to improving access to gonorrhea therapeutics, including diagnostics, treatments, and preventive strategies.

Major companies operating in the gonorrhea therapeutics market are Pfizer Inc., F Hoffmann La Roche Ltd, GlaxoSmithKline plc, Aurobindo Pharma Limited, Melinta Therapeutics LLC, VenatoRx Pharmaceuticals Inc., Recce Pharmaceuticals Ltd., Therapyx Inc., Entasis Therapeutics Inc., Apotex Inc., Summit Therapeutics Inc., Merck Co Inc, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Novartis AG, Sanofi S A, Bayer AG, Nobelex Biotech, Evofem Biosciences Inc., NextGen Pharma.

North America was the largest region in the gonorrhea therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gonorrhea therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gonorrhea therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the gonorrhea therapeutics market by increasing costs of imported antibiotics, diagnostic reagents, and laboratory supplies. Hospitals and clinics are most affected due to reliance on imported medications. These tariffs increase treatment costs by raising drug procurement and diagnostic expenses, potentially affecting timely infection management and antimicrobial resistance control. However, they support domestic antibiotic manufacturing, strengthening local production capacity for essential anti-infective drugs.

The gonorrhea therapeutics market research report is one of a series of new reports that provides gonorrhea therapeutics market statistics, including gonorrhea therapeutics industry global market size, regional shares, competitors with a gonorrhea therapeutics market share, detailed gonorrhea therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the gonorrhea therapeutics industry. This gonorrhea therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gonorrhea therapeutics are treatments and medications developed to manage and cure gonorrhea, a sexually transmitted infection (STI) caused by the bacterium Neisseria gonorrhoeae. These therapies primarily involve antibiotics, often used in combination to prevent resistance and ensure the effective elimination of the bacteria.

The main classes of gonorrhea therapeutics include antibiotics, combination therapy, and monotherapy. Antibiotics are medications specifically aimed at treating and eradicating the bacteria responsible for gonorrhea, commonly including drugs such as azithromycin and ceftriaxone. These treatments are administered via various routes, including oral, intravenous, and intramuscular methods, and are intended for different age groups, such as pediatric, adult, and geriatric patients. Distribution channels for these therapeutics include hospital pharmacies, retail pharmacies, and online pharmacies, with primary end users being hospitals, clinics, and home care settings.

The gonorrhea therapeutics market consists of revenues earned by entities by providing services such as diagnostic testing services, sexual health and counseling services, telemedicine, and online consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The gonorrhea therapeutics market also includes sales of pediatric formulations, single-dose regimens, sulfonamides, and penicillin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.